高密度脂蛋白和低密度脂蛋白纳米复合物作为抗癌靶向药物载体的研究进展  

Advances in research of high density lipoprotein and low density lipoprotein nano-complexes as anti-cancer drug targeting carriers

作　　者：刘畅[1] 李圣男[1] 王洋[1] 陈烨[1] LIU Chang LI Sheng-nan WANG Yang CHEN Ye(College of Pharmacy of Liaoning University, New Drug R＆D Key Laboratory of Liaoning Province, Shenyang 110036, China)

机构地区：[1]辽宁大学药学院辽宁省新药研发重点实验室,沈阳110036

出　　处：《中国新药杂志》2017年第3期285-290,共6页Chinese Journal of New Drugs

基　　金：国家"重大新药创制"重大科技专项资助项目(2009ZX09103-030);辽宁省教育厅高等学校创新团队项目(LT2015011)

摘　　要：高密度脂蛋白和低密度脂蛋白,作为人体内源性的脂蛋白颗粒,具有毒性低、选择性高、安全性良好、能够避免人体网状内皮系统的识别清除等特点。其作为纳米靶向给药载体的研究受到广泛关注,本文主要介绍了近年来基于这两类脂蛋白以及重组脂蛋白作为靶向给药载体在抗癌领域的最新研究进展。As human endogenous lioporoteins,high density lipoprotein and low density lipoprotein are of low toxicity,high selectivity,strong safety and have the ability to escape the recognition or elimination by the reticuloendothelial system. They have received more and more attention in the field of nano-targeting carriers. This article summarizes the advances in the research of high density lipoprotein（HDL）,low density lipoprotein（LDL）and reconstituted HDL as targeting carriers in the past several years.

关 键 词：高密度脂蛋白 低密度脂蛋白 抗癌 纳米复合物 靶向载体 

分 类 号：R944[医药卫生—药剂学]